Biostar Pharmaceuticals, Inc. Announces Its Full Year And Fourth Quarter 2014 Financial Results

XIANYANG, China, April 15, 2015 /PRNewswire/ -- Biostar Pharmaceuticals, Inc. (BSPM) ("Biostar", "we" or the "Company"), a manufacturer and marketer of pharmaceutical and health supplements to treat a variety of diseases and ailments, headquartered in China, today announced its results of operations for the full year and the quarter ended December 31, 2014.

Mr. Ronghua Wang, Chairman and CEO of Biostar Pharmaceuticals, Inc. commented: "In 2014, we experienced double digit growth in both our top line and gross profit.  We believe our positive results are the fruits of labor from our loyal and experienced team at Biostar.  By hitting 16.5% growth in sales, we were able to achieve and exceed our internal sales targets. Despite certain write-offs and one off dispositions, we were able to achieve net profit margins of 7.89%.  We believe the Company has returned to normal sustainable profit margins after weathering the storm in 2012 that adversely affected our entire industry.  We do believe through market research and input from our customers, vendors, industry experts, we were able to adapt to the market by, among other things, developing and introducing several new products to the market.  We also executed on a new sales strategy which included rolling out revised incentive compensation structure for our sales team and sales channels."

"In 2015, the Company will continually re-examine its product portfolio to focus on high margin products and expand its national sales footprint.  The Company will look to grow sales for its products via e-commerce.  Of course, the Company will not remain static with its core competency the research and development of new drugs. The Company also believes that economies of scale is vital to continue to improve its bottom line; accordingly, when the right opportunity presents itself, the Company will consider acquiring competitors to ramp up its production." In closing, Chairman Wang noted: "We will make every effort to make 2015 a banner year so that we can bring superior returns to all of our stakeholders."

*The Company's Consolidated Balance Sheets, Statement of Operations, and Cash Flows can be found at the end of this press release.  Please also refer the Company's Annual Report on Form 10K filed with the U.S. Securities and Exchange Commission for further regarding the Company's results of operations and the potential risks of investing in the Company's common stock.

About Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly owned subsidiary and controlled affiliate in China, develops, manufactures and markets pharmaceutical and health supplement products for a variety of diseases and conditions. The Company's most popular product is its Xin Aoxing Oleanolic Acid Capsule, an over-the-counter ("OTC") medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. For more information please visit: http://www.biostarpharmaceuticals.com.

Safe Harbor Relating to the Forward-Looking Statements

Certain statements in this release concerning our future growth prospects are forward-looking statements, within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The company uses words and phrases such as "guidance," "forecasted," "projects," "is expected," "remain confident," "will" and similar expressions to identify forward-looking statements in this press release, including forward-looking statements. Undue reliance should not be placed on forward-looking information. Forward-looking information is based on current expectations, estimates and projections that involve a number of risks, which could cause actual results to vary and in some instances to differ materially from those anticipated by Biostar and described in the forward-looking information contained in this news release. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the Company's ability to sustain its sales effort going forward, its ability to retain existing and retain new customers for its products, its ability to achieve the projected sales through the efforts of the call center, to complete the contemplated clinical trials and capitalize on such opportunities, the Company's ability to recover its sales and revenue for the gel capsule segment of its business, the state of consumer confidence and market demand or the Company's products, success of our investments, risks and uncertainties regarding fluctuations in earnings, our ability to sustain our previous levels of profitability including on account of our ability to manage growth, intense competition, wage increases in China, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, our ability to successfully complete and integrate potential acquisitions, withdrawal of governmental fiscal incentives, political instability and regional conflicts and legal restrictions on raising capital or acquiring companies outside China.

To read full press release, please click here.

Help employers find you! Check out all the jobs and post your resume.

Back to news